Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients

NCT02330783 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

106

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Renal Cell Carcinoma

Interventions

DRUG: Bevacizumab
DRUG: Sorafenib

Sponsor

Peking University Cancer Hospital & Institute